肾细胞癌脆性组氨酸三联体FHIT蛋白表达缺失的临床病理意义  

Clinicopathological significance of loss of expression of fragile histidine triad expression in renal cell cancer

作　　者：赵坡[1] 侯宁[1] 曹友俊[1] 

机构地区：[1]解放军总医院病理科,北京100853

出　　处：《肿瘤防治杂志》2005年第19期1486-1488,共3页China Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨肾细胞癌中脆性组氨酸三联体(fragile histidine triad,FHIT)基因蛋白表达状况及其与临床病理的关系。方法:采用兔抗人FHIT蛋白抗体和枸橼酸-微波-SP免疫组化方法检测86例肾细胞癌、52例癌旁组织和10例肾组织中FHIT的表达状况,并分析其与组织学分级、临床分期以及5年生存率的关系。结果:肾细胞癌FHIT表达较癌旁组织和正常肾组织明显降低,H=69·421,P=0·000。FHIT蛋白表达在肾癌组织学分型(H=11·557,P=0·003)、分级(H=13·402,P=0·001)及临床分期(H=18·168,P=0·000)中差异均有统计学意义。FHIT蛋白表达强阳性组患者5年生存率显著高于弱阳性及阴性组,Z=-2·390,P=0·017。结论:FHIT低表达或缺失可能提示其抑癌功能丧失,对肾细胞癌的发生和演化具有重要作用。FHIT表达缺失可能成为辅助肾细胞癌诊断及预后的一个新标记。肿瘤防治杂志,2005,12(19)OBJECTIVE： To investigate the expression of fragile histidine triad （FHIT） gene protein, and the possible relationship between FHIT expression and clinicopathologieal indices in renal cell carcinoma. METHODS： FHIT protein expression was detected in 86 renal cell carcinomas,52 adjacent non-neoplastic tissues and 10 normal kidney tissues formalin-fixed, paraffin-embedded tissues by the citratemicrowave-SP immunohistochemical method, and the relationship between it and histological grade, clinical stage and 5-year survival rate was analysed RESULTS： Thirty paint two percent （26/86） of renal cell carcinomas, 100. 0% （52/52） of parameoplastie tissues and 100.0% （10/10） of normal kidney tissues showed a strongly positive staining pattern of FHIT protein. There was a significant difference in FHIT expression between carcinomas and adjacent non-neoplastic tissues or normal kidney, H = 69. 421, P = 0. 000. Carcinomas with decreased expression of FHIT were corresponding to the histological type （ H= 11. 557, P=0.003）, histological grade （H=13.402, P=0.001）, clinical stage （H=18. 168, P=0.000） and 5-year survival rate （Z= -2. 390, P=0.017）, respectively. CONCLUSION： The loss of expression of FHIT may be associated with the carcinogenesis of tubule epithelia, the development and the prognosis of the tumor, thus may become a new adjunct diagnostic and prognostic marker in renal cell carcinoma.

关 键 词：癌 肾细胞/治疗 肾肿瘤/病理学 免疫学试验 存活率 

分 类 号：R737.11[医药卫生—肿瘤]